227 / 238
227
11–14 APRIL, 2018, HELSINKI, FINLAND
Current study
Defoor 2006
P value
(Chi-squared test)
Number of patients (Male:Female)
17 (9M: 8F)
80 (38M: 42F)
Median age (years)
4.2 (0.7-10.7)
10 (0.3-36)
Median duration (days)
51 (7-227)
90
Indwelling or SP catheter
6 (35 %)
11 (14 %)
Elevated gentamicin levels > 0.4 mg/dL
0 %
0 %
Breakthrough UTI
4 (24 %)
21 (26 %)
0.82
Gentamicin resistance
1 (6 %)
5 (6 %)
0.95
CONCLUSIONS
There was no difference in the safety or efficacy of intra-vesical gentamicin therapy between the
current study and published literature (Defoor 2006). Intra-vesical gentamicin therapy is a safe
feasible option in children with recurrent urinary tract infections and complex urological conditions.